GUILFORD, Conn.–(BUSINESS WIRE)–Mar. 24, 2023–
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in B. Riley Securities’ Life Sciences Tools Conference – Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.
Patrick Schneider, Ph.D., Quantum-Si’s President and Chief Operating Officer, will participate in the panel discussion “How to Translate Insights from Proteomics and Advances in AI into Drug Discovery and Innovation?” at 10:30 AM ET.
Additionally, Jeff Hawkins, Quantum-Si’s Chief Executive Officer, and Dr. Schneider will participate in a fireside chat at 2:30 PM ET.
A link for live and archived webcasts of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantumsi.supremeclients.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005113/en/
Investor
Juan Avendano
[email protected]
Media
Michael Sullivan
[email protected]
Source: Quantum-Si Incorporated